Press Releases

-- Primary Phase 3 trial will focus on studying 24-week telaprevir-based regimens -- Vertex plans concurrent second study to support registration -- Final data from both trials anticipated in mid- 2010

- Formal European scientific advice obtained for telaprevir development program - - Meeting scheduled with FDA for January 2008 on Phase 3 trial design and recent data - - Next-generation HCV protease inhibitor and two investigational compounds for cystic fibrosis in clinical development -

CAMBRIDGE, Mass., Jan 03, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 26th Annual JPMorgan Healthcare Conference on Monday, January 7, 2008 at 2:00 p.m. PST (5:00 p.m. EST).

CAMBRIDGE, Mass., Nov 21, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the CIBC World Markets 3rd Annual Mid & Small Cap 'Best Ideas' Conference on Wednesday, November 28, 2007 at 8:45 a.m. EST.

-- Companies continue broad program to develop investigational Aurora kinase inhibitors as novel treatments for a range of cancers -- -- Merck to initiate clinical development of VX-689 --

Cambridge, MA, November 5, 2007 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentations at the 9th Annual MASS Opportunities Investment Conference on Thursday, November 8, 2007 at 2:45 p.m.

Two Large Phase 2 Trials of Telaprevir, an Investigational Hepatitis C Protease Inhibitor, Dosed in Combination with Pegylated Interferon and Ribavirin Show SVR Rates of 61% and 65% Initial Rapid Viral Decline Appears Important to Achieve SVR Safety Profile Consistent with Prior Interim Analyses

Vertex Pharmaceuticals Reports Third Quarter 2007 Financial Results and Provides Development Pipeline Update Important telaprevir data to be presented at AASLD – Additional compounds for HCV and Cystic Fibrosis scheduled to enter development – Cambridge, MA, October 29, 2007 — Vertex

CAMBRIDGE, Mass., Oct 09, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2007 financial results on Monday, October 29, 2007 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.

-- Conference Presentations to Include Data from Two Randomized, Controlled Phase 2 Clinical Studies of Investigational HCV Protease Inhibitor Telaprevir --

CAMBRIDGE, Mass., Sep 14, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentations at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference on Tuesday, September 18th at 1:00 p.m. GMT (8:00 a.m.

CAMBRIDGE, Mass., Sep 05, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Bear Stearns 20th Annual Healthcare Conference on Monday, September 10th at 3:00 p.m. EDT.

CAMBRIDGE, Mass., Jul 24, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2007, and the Company provided a pipeline update. "Vertex achieved its major development pipeline milestones in the first

CAMBRIDGE, Mass., Jul 09, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its second quarter 2007 financial results on Tuesday, July 24, 2007 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.

CAMBRIDGE, Mass., Jun 29, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Kurt C. Graves as Executive Vice President, Chief Commercial Officer and Head, Strategic Development. Vertex also announced today that Amit K.

-- More than 1000 patients have now been enrolled in Phase 2b PROVE trials -- More than 350 patients have completed 12 weeks of telaprevir dosing in PROVE trials -- Interim results from PROVE 2 consistent with findings from PROVE 1

CAMBRIDGE, Mass., Jun 01, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentations at the Bear Stearns Biotech Confab on Thursday, June 7th at 7:50 a.m. EDT and at the Goldman Sachs 28th Annual Global Healthcare Conference on Wednesday, June 13th at

CAMBRIDGE, Mass., May 31, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2007 Annual Meeting of Stockholders. At the meeting, stockholders re-elected Joshua Boger, Ph.D., Charles A. Sanders, M.D., and Elaine S.

CAMBRIDGE, Mass., May 17, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentation at Citigroup's 2007 Global Healthcare Conference on May 23, 2007 at 4:00 p.m. EDT. The presentation will be webcast live and may be accessed from the 'Events Calendar'

CAMBRIDGE, Mass., Apr 30, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2007. "In 2007, a major goal for Vertex is to build the product profile of the investigational hepatitis C protease